SFX by Ex Libris Inc.

Title:	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Source:	Nature Genetics [1061-4036] Abifadel, Marianne yr:2003

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Cohen, J. "Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9." Nature genetics 37.2 (2005): 161-5.
description	2.	Cameron, J. "Effect of mutations in the PCSK9 gene on the cell surface LDL receptors." Human Molecular Genetics 15.9 (2006): 1551-8.
description	3.	Rabès, Jean-Pierre P. "Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia." Human mutation 26.5 (2005): 497-497.
description	4.	Dedoussis, George V Z V. "LDL-receptor mutations in Europe." Human mutation 24.6 (2005): 443-59.
description	5.	Nordestgaard, B G G. "Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease." The New England journal of medicine 339.22 (1998): 1577-84.
description	6.	Cohen, Jonathan C C. "Sequence variations in PCSK9, low LDL, and protection against coronary heart disease." The New England journal of medicine 354.12 (2006): 1264-72.
description	7.	Stein, Evan A. "Effect of a monoclonal antibody to PCSK9 on LDL cholesterol." The New England journal of medicine 366.12 (2012): 1108-1118.
description	8.	Hooper, Amanda J J. "The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population." Atherosclerosis 193.2 (2007): 445-8.
description	9.	Zhao, Z. "Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote." American journal of human genetics 79.3 (2006): 514-23.
description	10.	Deanfield, J E E. "Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis." The lancet 340 (1992): 1111-1115.
description	11.	Berge, Knut Erik E. "Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy." Arteriosclerosis, thrombosis, and vascular biology 26.5 (2006): 1094-100.
description	12.	Handberg, A. "Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance." Circulation 114.11 (2006): 1169-76.
description	13.	Brown, M. "Biomedicine. Lowering LDL--not only how low, but how long?" Science 311.5768 (2006): 1721-3.
description	14.	Endo, S. "Bone regeneration by modified gene-activated matrix: Effectiveness in segmental tibial defects in rats." Tissue engineering 12.3 (2006): 489-497.
description	15.	Varret, M. "Genetic heterogeneity of autosomal dominant hypercholesterolemia." Clinical genetics 73.1 (2008): 1-13.
description	16.	Wilmshurst, Heinz M. "RYR1 mutations are a common cause of congenital myopathies with central nuclei." Annals of neurology 68.5 (2010): 717-726.
description	17.	Vaithinathan, R. "Further screening of the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa." Genomics 21.2 (1994): 461-463.
description	18.	Civeira, F. "Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia." The American journal of cardiology 102.9 (2008): 1187-1193.
description	19.	Pearson, Thomas A A. "A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial." Mayo Clinic proceedings 80.5 (2005): 587-95.
description	20.	Ridker, P M M. "C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women." The New England journal of medicine 342.12 (2000): 836-43.